This morning, Reunion Neuroscience shared positive topline data from its Phase 2 trial of RE104 in postpartum depression (PPD), a study that saw 84 female patients with moderate to severe PPD enrolled across 38 U.S. sites (NCT06342310; ‘RECONNECT’).

RE104, the company’s lead candidate, is a prodrug of 4-OH-DiPT, one of Sasha Shulgin’s TiHKAL compounds. With a duration of several hours, the drug has a shorter subjective experience than the likes of psilocybin, but longer than psychedelics like DMT or 5-MeO-DMT.

The trial saw a single dose of RE104 delivered via subcutaneous injection at either a 30 mg or 1.5 mg dose, with the latter positioned as an active control. Patients were followed for 28 days, with the primary endpoint being MADRS change from baseline to day 7. The company dosed the first patient in the trial last July.

Here, we review the topline data and share our discussion with Reunion management…